Metabolism and disposition of 3,4-methylenedioxymethamphetamine ("ecstasy") in baboons after oral administration: Comparison with humans reveals marked differences

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 1, 2011, Pages 310-317

  Mueller, Melanie ^a   Goodwin, Amy K ^a   Ator, Nancy A ^a   McCann, Una D ^a   Ricaurte, George A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXY 3 METHOXYMETHAMPHETAMINE; AMPHETAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BABOON; BIOTRANSFORMATION; BLOOD LEVEL; CONTROLLED STUDY; DEMETHYLATION; EXPOSURE; FIRST PASS EFFECT; HALF LIFE TIME; HUMAN VERSUS ANIMAL COMPARISON; MALE; METHYLATION; NONHUMAN; PRIORITY JOURNAL; XENOBIOTIC METABOLISM;

ADMINISTRATION, ORAL; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PAPIO HAMADRYAS; SPECIES SPECIFICITY; TISSUE DISTRIBUTION;

EID: 79959521743     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.180612     Document Type: Article

References (40)

1. Banks ML, Sprague JE, Kisor DF, Czoty PW, Nichols DE, and Nader MA (2007) Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys. Drug Metab Dispos 35:1840-1845. (Pubitemid 47481576)
2. Beardsley PM, Balster RL, and Harris LS (1986) Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys. Drug Alcohol Depend 18:149-157. (Pubitemid 16002930)
3. Capela JP, Carmo H, Remião F, Bastos ML, Meisel A, and Carvalho F (2009) Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol 39:210-271.
4. Chu T, Kumagai Y, DiStefano EW, and Cho AK (1996) Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol 51:789-796. (Pubitemid 26094447)
5. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, and Seiden LS (1987) Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 241:338-345. (Pubitemid 17119380)
6. de la Torre R and Farré M (2004) Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 25:505-508.
7. de la Torre R, Farré M, Ortuño J, Mas M, Brenneisen R, Roset PN, Segura J, and Camí J (2000a) Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 49:104-109.
8. de la Torre R, Farre M, Roset PN, Lopez CH, Mas M, Ortuno J, Menoyo E, Pizarro N, Segura J, and Cami J (2000b) Pharmacology of MDMA in humans. Ann N Y Acad Sci 914:225-237.
9. Fantegrossi WE (2007) Reinforcing effects of methylenedioxy amphetamine congeners in rhesus monkeys: are intravenous self-administration experiments relevant to MDMA neurotoxicity? Psychopharmacology (Berl) 189:471-482.
10. Fantegrossi WE, Ullrich T, Rice KC, Woods JH, and Winger G (2002) 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology (Berl) 161:356-364.
11. Green AR, Mechan AO, Elliott JM, O'Shea E, and Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55:463-508. (Pubitemid 37013213)
12. Heydari A, Yeo KR, Lennard MS, Ellis SW, Tucker GT, and Rostami-Hodjegan A (2004) Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab Dispos 32:1213-1217. (Pubitemid 39410904)
13. Kalant H (2001) The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. CMAJ 165:917-928.
14. 11C]DASB and structural brain imaging study. Brain 133:1779-1797.
15. Kleven MS, Woolverton WL, and Seiden LS (1989) Evidence that both intragastric and subcutaneous administration of methylenedioxymethylamphetamine (MDMA) produce serotonin neurotoxicity in rhesus monkeys. Brain Res 488:121-125. (Pubitemid 19136794)
16. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, and Huestis MA (2008a) Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol 28:432-440.
17. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, and Huestis MA (2008b) Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit 30:320-332.
18. Lamb RJ and Griffiths RR (1987) Self-injection of d,1-3,4- methylenedioxymethamphetamine (MDMA) in the baboon. Psychopharmacology (Berl) 91:268-272. (Pubitemid 17018090)
19. Lile JA, Ross JT, and Nader MA (2005) A comparison of the reinforcing efficacy of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") with cocaine in rhesus monkeys. Drug Alcohol Depend 78:135-140. (Pubitemid 40544600)
20. Mahmood I and Balian JD (1999) The pharmacokinetic principles behind scaling from preclinical results to phase I protocols. Clin Pharmacokinet 36:1-11. (Pubitemid 29055997)
21. 11C]DASB. Neuropsychopharmacology 30:1741-1750.
22. Mechan A, Yuan J, Hatzidimitriou G, Irvine RJ, McCann UD, and Ricaurte GA (2006) Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. Neuropsychopharmacology 31:339-350. (Pubitemid 43113398)
23. Meyer MR and Maurer HH (2009) Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation. Chem Res Toxicol 22:1205-1211.
24. Meyer MR, Peters FT, and Maurer HH (2008) The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy- methamphetamine and its enantiomers. Drug Metab Dispos 36:2345-2354.
25. Mordenti J (1986) Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 75:1028-1040.
26. Mordenti J and Chappell W (1989) The use of interspecies scaling in toxicokinetics, in Toxicokinetics in New Drug Development (Yacobi A, Kelly J, and Batra V eds) pp 42-96, Pergamon Press, New York.
27. Morefield KM, Keane M, Felgate P, White JM, and Irvine RJ. (2011) Pill content, dose, and resulting plasma concentrations of MDMA in recreational "ecstasy" users. Addiction doi:10.1111/j.1360-0443.2011.03399.x.
28. Mueller M, Kolbrich EA, Peters FT, Maurer HH, McCann UD, Huestis MA, and Ricaurte GA (2009a) Direct comparison of (±)-3,4- methylenedioxymethamphetamine ("ecstasy") disposition and metabolism in squirrel monkeys and humans. Ther Drug Monit 31:367-373.
29. Mueller M, Peters FT, Huestis MA, Ricaurte GA, and Maurer HH (2009b) Simultaneous liquid chromatographic-electrospray ionization mass spectrometric quantification of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and its metabolites 3,4-dihydroxymethamphetamine, 4-hydroxy-3-methoxymethamphetamine and 3,4-methylenedioxyamphetamine in squirrel monkey and human plasma after acidic conjugate cleavage. Forensic Sci Int 184:64-68.
30. Mueller M, Peters FT, Maurer HH, McCann UD, and Ricaurte GA (2008) Nonlinear pharmacokinetics of (±)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses. J Pharmacol Exp Ther 327:38-44.
31. Mueller M, Peters FT, Ricaurte GA, and Maurer HH (2007) Validated liquid chromatographic-electrospray ionization mass spectrometric assay for simultaneous determination of 3,4-methylenedioxymethamphetamine and its metabolites 3,4-methylenedioxyamphetamine, 3,4-dihydroxymethamphetamine, and 4-hydroxy-3-methoxymethamphetamine in squirrel monkey plasma. J Chromatogr B Analyt Technol Biomed Life Sci 855:262-270. (Pubitemid 47212023)
32. Mueller M, Yuan J, Felim A, Neudörffer A, Peters FT, Maurer HH, McCann UD, Largeron M, and Ricaurte GA (2009) Further studies on the role of metabolites in (±)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity. Drug Metab Dispos 37:2079-2086.
33. Ramamoorthy Y, Yu AM, Suh N, Haining RL, Tyndale RF, and Sellers EM (2002) Reduced (±)-3,4-methylenedioxymethamphetamine ("Ecstasy" ) metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem Pharmacol 63:2111-2119. (Pubitemid 34756676)
34. Samyn N, De Boeck G, Wood M, Lamers CT, De Waard D, Brookhuis KA, Verstraete AG, and Riedel WJ (2002) Plasma, oral fluid and sweat wipe ecstasy concentrations in controlled and real life conditions. Forensic Sci Int 128:90-97.
35. Scheffel U, Szabo Z, Mathews WB, Finley PA, Dannals RF, Ravert HT, Szabo K, Yuan J, and Ricaurte GA (1998) In vivo detection of short- and long-term MDMA neurotoxicity-a positron emission tomography study in the living baboon brain. Synapse 29:183-192.
36. Schenk S, Hely L, Lake B, Daniela E, Gittings D, and Mash DC (2007) MDMA self-administration in rats: acquisition, progressive ratio responding and serotonin transporter binding. Eur J Neurosci 26:3229-3236. (Pubitemid 350135177)
37. Schmidt CJ (1987) Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 240:1-7.
38. Substance Abuse and Mental Health Services Administration (2010) Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. NSDUH Series H-38A, HHS Publication No. SMA 10-4856Findings. Office of Applied Studies, Rockville, MD.
39. 11C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med 43:678-692.
40. Turkkan JS, Ator NA, Brady JV, and Craven KA. (1989) Beyond chronic catheterization in laboratory primates, in Housing, Care, and Psychological Wellbeing of Captive and Laboratory Primates (Segal EF ed) pp 305-322, Noyes Publication, Park Ridge, NJ.